Texas Oncology - Northeast Texas

The trials here

What the 9 trials at this site are about, from their registry records.

Conditions

• Lung cancer4 trials
• Metastatic breast cancer2 trials
• Colorectal cancer1 trial
• Ovarian cancer1 trial
• Pancreatic cancer1 trial

Phase

• Phase 37 trials
• Phase 1/21 trial
• Phase 2/31 trial

Status

• Recruiting6 trials
• Active, not recruiting2 trials
• Enrolling by invitation1 trial

Lead sponsor

• Pfizer6 trials
• Hoffmann-La Roche1 trial
• Revolution Medicines, Inc.1 trial
• Tolmar Inc.1 trial

Running trials

• Recruiting

  Symbiotic-Lung-01 : A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT07222566· Phase 3· Pfizer· Source

• Recruiting

  Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC)

  NCT07252232· Phase 3· Revolution Medicines, Inc.· Source

  Contact: Angie Smith

• Recruiting

  Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

  NCT07222800· Phase 3· Pfizer· Source

• Recruiting

  Symbiotic-Lung-04: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer

  NCT07226999· Phase 2/3· Pfizer· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)

  NCT07144280· Phase 3· Pfizer· Source

• Recruiting

  A Study to Learn About the Study Medicine Called PF-07248144 in Combination With Fulvestrant in People With HR-positive, HER2-negative Advanced or Metastatic Breast Cancer Who Progressed After a Prior Line of Treatment.

  NCT07062965· Phase 3· Pfizer· Source

• Active, not recruiting

  A Study of Disitamab Vedotin in Adults With HER2 Expressing Advanced Breast Cancer

  NCT06966453· Phase 1/2· Pfizer· Source

• Active, not recruiting

  A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer

  NCT06497556· Phase 3· Hoffmann-La Roche· Source

• Enrolling by invitation

  Safety Extension Study for Subjects With HR+, HER2- Breast Cancer for Subjects Who Have Completed the OVELIA Study

  NCT05645536· Phase 3· Tolmar Inc.· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Lung cancer3 recruiting
• Colorectal cancer1 recruiting
• Metastatic breast cancer1 recruiting
• Ovarian cancer1 recruiting
• Pancreatic cancer1 recruiting